MedTrace Logo

Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population

NCT03682939 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2019-04-10

No results posted yet for this study

Summary

This study aims to evaluate the immunogenicity, safety and tolerability of co-administration of vaccinations for meningitis B (Bexsero®) and meningitis ACWY (Menveo®) in adults and children aged 10-45 years living with HIV. All participants will be vaccinated with both Menveo® and Bexsero® on days 0 and 30. Immunogenicity will be determined on venous blood sampled at days 0 and 60. Adverse effects will be recorded to evaluate safety.

Conditions

  • Hiv
  • Meningitis, Meningococcal
  • HIV Infections

Interventions

BIOLOGICAL

Bexsero® (meningitis B vaccine)

Bexsero® 0.5ml IM vaccine administered into non-dominant arm of participant

BIOLOGICAL

Menveo® (meningitis ACWY vaccine)

Menveo® 0.5ml IM vaccine administered into dominant arm of participant

Sponsors & Collaborators

  • St George's, University of London

    lead OTHER

Principal Investigators

  • Catherine Cosgrove, MBBS PhD · St George's, University of London

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-21
Primary Completion
2020-06-30
Completion
2021-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03682939 on ClinicalTrials.gov